AbbVie has received an exciting set of FDA approvals over the past few weeks which have made the company’s stock soar. In the first week of December 2021, the company announced the approval of its Vuity 1.25% prescription eye drop, the first and only FDA-approved eye drop to treat presbyopia – age-related blurry vision. AbbVie also received approval for its Rinvoq (upadacitinib; 15 mg) medication to treat patients of active psoriatic arthritis. Apart from these big approval announcements which a ....
25 Dec 2021
AbbVie Inc: An Exciting New Set Of Approvals (12/2021)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
AbbVie Inc: An Exciting New Set Of Approvals (12/2021)
- Published:
25 Dec 2021 -
Author:
Ishan Majumdar -
Pages:
14
AbbVie has received an exciting set of FDA approvals over the past few weeks which have made the company’s stock soar. In the first week of December 2021, the company announced the approval of its Vuity 1.25% prescription eye drop, the first and only FDA-approved eye drop to treat presbyopia – age-related blurry vision. AbbVie also received approval for its Rinvoq (upadacitinib; 15 mg) medication to treat patients of active psoriatic arthritis. Apart from these big approval announcements which a ....